好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Case-based Medical 好色先生 Improves Neurologists’ Competence in Diagnosing and Managing Levodopa-induced Dyskinesia
Movement Disorders
P5 - Poster Session 5 (5:30 PM-6:30 PM)
10-036

The current study was undertaken to determine if an online case-based medical education activity could improve the ability to recognize and effectively manage LID in patients with PD.

Levodopa is the standard of care to improve motor symptoms in patients with Parkinson’s disease (PD), but chronic use is associated with the emergence of involuntary movements called levodopa-induced dyskinesia (LID).

The intervention comprised 2 patient case scenarios in an online, interactive, text-based CME activity. Using a “test and teach” methodology, clinicians were presented with multiple-choice questions to test their application of evidence-based recommendations. Each response was followed by education in the form of detailed, referenced feedback. A paired 2-tailed t-test evaluated differences in pre- and post-assessment answer choices and McNemar’s test measured changes in paired responses to individual questions. Cramer’s V was used to calculate the effect size of the intervention. Data from the educational intervention were collected between June 15, 2018 and July 24, 2018.

Comparison of responses to questions before and after education demonstrated statistically significant improvements and an extensive educational effect for neurologists (n=110; P <.001; V =.342). Significant increases in knowledge and competence were observed in several specific areas (P <.05 for all comparisons): recognition of clinical symptoms indicative of LID; selection of amantadine as therapy for LID after levodopa dose adjustment; and differentiation of the available formulations of amantadine. Participation in this activity resulted in 35% of neurologists reporting an improvement in confidence to identify the clinical value of different amantadine formulations for the management of LID.

This study demonstrated the success of an online, interactive, case-based educational activity at improving the competence of neurologists regarding the diagnosis and treatment of LID. Future education should continue to focus on symptom recognition and management strategies for LID.
Authors/Disclosures

PRESENTER
No disclosure on file
Thomas Finnegan, Jr., PhD (Medscape 好色先生) Dr. Finnegan has nothing to disclose.
No disclosure on file
Rajesh Pahwa, MD, FAAN (University of Kansas Medical Center) Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbott. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AbbVie. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for ACADIA. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Amneal. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Supernus. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Insightec. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jaaz. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Fasikl. Dr. Pahwa has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genetech. Dr. Pahwa has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Pahwa has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Photopharmics. The institution of Dr. Pahwa has received research support from Abbott. The institution of Dr. Pahwa has received research support from Abbvie. The institution of Dr. Pahwa has received research support from Biogen. The institution of Dr. Pahwa has received research support from Parkinson Foundation. The institution of Dr. Pahwa has received research support from Roche. The institution of Dr. Pahwa has received research support from Sage. The institution of Dr. Pahwa has received research support from Sun Pharma. The institution of Dr. Pahwa has received research support from Theravance. The institution of Dr. Pahwa has received research support from Neuroderm. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Blue Rock. The institution of Dr. Pahwa has received research support from Cerevance. The institution of Dr. Pahwa has received research support from Fasikl. The institution of Dr. Pahwa has received research support from Scion. The institution of Dr. Pahwa has received research support from UCB. The institution of Dr. Pahwa has received research support from Ono. The institution of Dr. Pahwa has received research support from Intra-cellular Therapies. The institution of Dr. Pahwa has received research support from Ask Bio. The institution of Dr. Pahwa has received research support from Michael J Fox Foundation . The institution of Dr. Pahwa has received research support from Neuron 23. The institution of Dr. Pahwa has received research support from Roche.